Corporate Audits Of Genomic Ip.
1. Understanding Corporate Audits of Genomic IP
Genomic IP refers to intellectual property related to genetic sequences, gene editing technologies (like CRISPR), diagnostics, synthetic biology, and related biotechnologies.
Corporate audits of genomic IP are internal or external reviews performed by companies to:
Assess the strength, scope, and validity of genomic patents.
Identify potential infringement risks or freedom-to-operate issues.
Evaluate opportunities for licensing, collaboration, or monetization.
Ensure regulatory compliance in different jurisdictions.
Strategically manage patent portfolios for R&D or M&A activity.
Audits usually cover patents, pending applications, trade secrets, and licensing agreements.
2. Key Strategies in Corporate Audits
A. Portfolio Mapping
Map all genomic patents, applications, and trade secrets.
Identify overlapping claims and redundancies.
Focus on key areas like gene editing methods, diagnostics, or synthetic biology platforms.
B. Validity & Strength Assessment
Check novelty, non-obviousness, and enablement of patents.
Analyze prior art, scientific publications, and earlier filings.
C. Freedom-to-Operate (FTO) Analysis
Assess whether current or planned research may infringe third-party patents.
Identify areas where licenses or collaborations are required.
D. Licensing & Monetization Review
Evaluate patents for potential licensing revenue or strategic alliances.
Prioritize patents with strong claims in emerging genomic technologies.
E. Compliance & Risk Management
Ensure patents comply with local and international laws, including biotech regulations.
Identify potential litigation risks, especially in high-stakes areas like CRISPR or diagnostic patents.
3. Case Illustrations
Case 1: Myriad Genetics v. Association for Molecular Pathology (2013)
Background: Myriad’s patents on isolated BRCA1 and BRCA2 gene sequences were challenged.
Audit/Relevance: Companies performing corporate audits would evaluate the validity of naturally occurring gene patents.
Outcome: U.S. Supreme Court ruled that naturally occurring DNA is not patentable, but cDNA (synthetic DNA) is.
Lesson: Corporate audits must distinguish natural genes vs. synthetic constructs to assess patent enforceability.
Case 2: CRISPR-Cas9 Dispute: Broad Institute v. University of California (2017)
Background: Competing patents on CRISPR gene-editing technology led to interferences.
Audit/Relevance: Companies with CRISPR IP must audit for overlapping claims, priority dates, and licensing rights.
Outcome: The Patent Trial and Appeal Board awarded priority for certain eukaryotic applications to Broad.
Lesson: Corporate audits help clarify ownership, avoid infringement, and inform licensing strategy.
Case 3: Amgen v. Sanofi/Regeneron (2019)
Background: Amgen alleged patent infringement of PCSK9 inhibitors used in cholesterol-lowering drugs.
Audit/Relevance: Corporate audits identified strength of patent claims and potential enforcement against competitors.
Outcome: Settlement reached after evaluating patent scope and litigation risks.
Lesson: Audits help quantify portfolio value and litigation exposure before enforcing patents.
Case 4: Sequenom v. Ariosa Diagnostics (2015)
Background: Sequenom patented non-invasive prenatal testing (NIPT) using cell-free fetal DNA.
Audit/Relevance: Audits highlighted the need to evaluate method patent enforceability in light of prior art.
Outcome: Federal Circuit invalidated claims for being directed to natural phenomena without sufficient inventive step.
Lesson: Corporate audits must identify patents vulnerable to invalidation for strategic planning.
Case 5: Monsanto v. DuPont (2018)
Background: Patents on genetically modified seeds and gene-editing methods.
Audit/Relevance: Corporate IP audits assessed ownership of gene-editing and breeding patents.
Outcome: Settlements and licensing agreements followed, with detailed review of patent scope across geographies.
Lesson: Audits support negotiation leverage and global enforcement strategy.
Case 6: Illumina v. BGI Genomics (2020)
Background: Dispute over next-generation sequencing patents and gene analysis technologies.
Audit/Relevance: Audit identified overlapping sequencing platform patents and potential infringement risks.
Outcome: Settlement and licensing agreements; strengthened IP portfolio management.
Lesson: Corporate audits are critical in fast-moving genomic tech sectors to identify enforcement opportunities.
Case 7: Editas Medicine v. CRISPR Therapeutics (2021)
Background: Dispute over CRISPR therapeutic applications.
Audit/Relevance: Corporate audits evaluated claims, patent lifespans, and freedom-to-operate for pipeline products.
Outcome: Cross-licensing enabled both parties to proceed with clinical development.
Lesson: Audits facilitate strategic collaboration and risk mitigation.
4. Key Takeaways for Corporate Audits of Genomic IP
Prioritize Patent Validity: Determine which patents are enforceable and which may be vulnerable to challenge.
Freedom-to-Operate Analysis: Audits prevent costly infringement in R&D or product launches.
Licensing & Monetization Strategy: Identify patents suitable for licensing or strategic partnerships.
Geographical Considerations: Genomic IP enforcement varies by country; audits help plan cross-border strategies.
Risk Assessment: Highlight patents exposed to legal challenges, natural product exclusions, or prior art.
Portfolio Optimization: Consolidate overlapping claims, identify gaps, and manage patent lifecycle.
RELATED Blog
comments